Search research articles
Contact Us
Filters
Showing results (61-70 of 92) with videos related to
Page
of 10
Sort By:
Cancer Discovery
|
August 11, 2018
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, et al.
British Journal of Cancer
|
September 4, 2021
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types
Christian Rolfo, Alexander Drilon, David Hong, et al.
Nature Cancer
|
June 21, 2022
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer
Aya Shiba-Ishii, Ted W Johnson, Ibiayi Dagogo-Jack, et al.
Nature Medicine
|
February 4, 2026
Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial
Benjamin Besse, Jessica J Lin, Lyudmila Bazhenova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2022
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
George D Demetri, Filippo De Braud, Alexander Drilon, et al.
JTO Clinical and Research Reports
|
November 18, 2020
Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations
Andrew J Piper-Vallillo, Meghan J Mooradian, Catherine B Meador, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 23, 2020
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
Ibiayi Dagogo-Jack, Satoshi Yoda, Jochen K Lennerz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 11, 2026
Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study
Sarah Waliany, Shambo Guha Roy, Federica Pecci, et al.
Future Oncology (London, England)
|
November 2, 2023
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study
Frank Griesinger, Giuseppe Curigliano, Vivek Subbiah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2018
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
Jessica J Lin, Viola W Zhu, Satoshi Yoda, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 92) with videos related to
Sort By:
Page
of 10
Cancer Discovery
|
August 11, 2018
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, et al.
British Journal of Cancer
|
September 4, 2021
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types
Christian Rolfo, Alexander Drilon, David Hong, et al.
Nature Cancer
|
June 21, 2022
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer
Aya Shiba-Ishii, Ted W Johnson, Ibiayi Dagogo-Jack, et al.
Nature Medicine
|
February 4, 2026
Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial
Benjamin Besse, Jessica J Lin, Lyudmila Bazhenova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2022
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
George D Demetri, Filippo De Braud, Alexander Drilon, et al.
JTO Clinical and Research Reports
|
November 18, 2020
Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations
Andrew J Piper-Vallillo, Meghan J Mooradian, Catherine B Meador, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 23, 2020
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
Ibiayi Dagogo-Jack, Satoshi Yoda, Jochen K Lennerz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 11, 2026
Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study
Sarah Waliany, Shambo Guha Roy, Federica Pecci, et al.
Future Oncology (London, England)
|
November 2, 2023
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study
Frank Griesinger, Giuseppe Curigliano, Vivek Subbiah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2018
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
Jessica J Lin, Viola W Zhu, Satoshi Yoda, et al.
Page
of 10